CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
9.54
-0.23 (-2.35%)
Apr 16, 2025, 11:33 AM EDT - Market open
CervoMed Revenue
In the year 2024, CervoMed had annual revenue of $9.74M with 36.29% growth. CervoMed had revenue of $2.16M in the quarter ending December 31, 2024, a decrease of -13.19%.
Revenue (ttm)
$9.74M
Revenue Growth
+36.29%
P/S Ratio
8.10
Revenue / Employee
$649,198
Employees
15
Market Cap
83.02M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.74M | 2.59M | 36.29% |
Dec 31, 2023 | 7.14M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCRVO News
- 15 days ago - Biotech Stocks Q1 2025 Recap: Winners And Underperformers - Seeking Alpha
- 22 days ago - CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™) - GlobeNewsWire
- 25 days ago - CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats - Seeking Alpha
- 5 weeks ago - CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies - GlobeNewsWire
- 2 months ago - CervoMed to Present at the 8th International Lewy Body Dementia Conference - GlobeNewsWire
- 4 months ago - CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets - Benzinga
- 4 months ago - CervoMed's stock craters 77% after failed trial of treatment for rare brain disease - Market Watch